BioNotebook: Puma boasts neratinib success in failed Phase II; and three other pipeline updates
This article was originally published in Scrip
Executive Summary
Puma Biotechnology president and CEO Alan Auerbach said the Los Angeles-based company is "very pleased with the results" of a Phase II breast cancer clinical trial in which neratinib failed to improve progression-free survival (PFS) versus Roche/Genentech's Herceptin (trastuzumab) despite a reduction in brain metastases.